Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Brilique

- PMLiVE

AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030

The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

UK and US agree on landmark pharma pricing tariff deal

US tariffs on UK-produced pharmaceuticals will remain at zero for three years

- PMLiVE

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

In 2022, nearly one million new patients were diagnosed with gastric cancer

- PMLiVE

AstraZeneca announces $2bn investment in US manufacturing

The new and expanded facilities will support production of rare disease drug treatments

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

AstraZeneca reports positive results from rare disease trial

HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

- PMLiVE

AstraZeneca reports positive results from phase 3 blood pressure trial

The study demonstrated reduction in systolic blood pressure compared to placebo in patient with hypertension

- PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

- PMLiVE

AstraZeneca to invest $4.5bn in US manufacturing facility

The investment will further support the company’s growing oncology pipeline

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links